Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma.
Hu L, Zhang Y, Guo L, Zhong H, Xie L, Zhou J, Liao C, Yao H, Fang J, Liu H, Zhang C, Zhang H, Zhu X, Luo M, von Kriegsheim A, Li B, Luo W, Zhang X, Chen X, Mendell JT, Xu L, Kapur P, Baldwin AS, Brugarolas J, Zhang Q. Hu L, et al. Among authors: guo l. Mol Cell. 2024 Feb 15;84(4):776-790.e5. doi: 10.1016/j.molcel.2023.12.010. Epub 2024 Jan 10. Mol Cell. 2024. PMID: 38211588
WILMS TUMOR MUTATIONAL SUBCLASSES CONVERGE TO DRIVE CCND2 OVEREXPRESSION.
Xu L, Desai K, Kim J, Zhou Q, Guo L, Xiao X, Zhang Y, Zhou L, Yuksel A, Catchpoole DR, Amatruda JF, Chen KS. Xu L, et al. Among authors: guo l. medRxiv [Preprint]. 2023 Feb 2:2023.01.30.23285117. doi: 10.1101/2023.01.30.23285117. medRxiv. 2023. PMID: 36778325 Free PMC article. Preprint.
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Lin CC, et al. Among authors: guo l. Res Sq [Preprint]. 2023 Jul 10:rs.3.rs-2966905. doi: 10.21203/rs.3.rs-2966905/v1. Res Sq. 2023. Update in: Nat Commun. 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2. PMID: 37502925 Free PMC article. Updated. Preprint.
Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
Dos Santos IL, Mitchell M, Nogueira PAS, Lafita-Navarro MC, Perez-Castro L, Eriom J, Kilgore JA, Williams NS, Guo L, Xu L, Conacci-Sorrell M. Dos Santos IL, et al. Among authors: guo l. FEBS J. 2024 May;291(10):2172-2190. doi: 10.1111/febs.17109. Epub 2024 Mar 3. FEBS J. 2024. PMID: 38431776
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Lin CC, et al. Among authors: guo l. Nat Commun. 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2. Nat Commun. 2024. PMID: 38480701 Free PMC article.
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.
Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, Buehler J, Stopka SA, Regan MS, Lin YF, Puliyappadamba VT, Gao W, Khanal J, Evans L, Lee JH, Guo L, Xiao Y, Xu M, Huang B, Jennings RB, Bonal DM, Martin-Sandoval MS, Dang T, Gattie LC, Cameron AB, Lee S, Asara JM, Kornblum HI, Mak TW, Looper RE, Nguyen QD, Signoretti S, Gradl S, Sutter A, Jeffers M, Janzer A, Lehrman MA, Zacharias LG, Mathews TP, Losman JA, Richardson TE, Cahill DP, DeBerardinis RJ, Ligon KL, Xu L, Ly P, Agar NYR, Abdullah KG, Harris IS, Kaelin WG Jr, McBrayer SK. Shi DD, et al. Among authors: guo l. Cancer Cell. 2022 Sep 12;40(9):939-956.e16. doi: 10.1016/j.ccell.2022.07.011. Epub 2022 Aug 18. Cancer Cell. 2022. PMID: 35985343 Free PMC article.
20,256 results
You have reached the last available page of results. Please see the User Guide for more information.